# Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Canonical URL: https://biopharmsignal.com/news/PRME/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates
Ticker: PRME
Company: Prime Medicine
Source: Prime Medicine
Published: 2026-05-07 12:00 EST
Original Source URL: https://investors.primemedicine.com
## Summary

-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 --   -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD --   -- Strengthened leadership team with

## Article Body
-- On track to file IND and/or CTA for PM577 in Wilson Disease in H1 2026 and for PM647 in AATD mid-2026; initial clinical data from both programs expected in 2027 --   -- Continued regulatory dialogue with the FDA toward BLA filing for PM359 in CGD --   -- Strengthened leadership team with
## Recent Company News
- 2026-06-03 12:00 EST — [Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/PRME/prime-medicine-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Prime Medicine
- 2026-05-07 12:00 EST — [Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/PRME/prime-medicine-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Prime Medicine
- 2026-04-16 12:00 EST — [Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer](https://biopharmsignal.com/news/PRME/prime-medicine-appoints-svetlana-makhni-as-chief-financial-officer) — Source: Prime Medicine
- 2026-03-03 13:00 EST — [Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/PRME/prime-medicine-reports-full-year-2025-financial-results-and-provides-business-updates) — Source: Prime Medicine
- 2026-02-25 13:00 EST — [Prime Medicine to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PRME/prime-medicine-to-participate-in-upcoming-investor-conferences) — Source: Prime Medicine
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)